あなたはここにいる:ホーム > お知らせ
07
28
2020
On July 20, 2020, DAC Biotech’s new ADC drug development, TROP2-ADC---DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process.
07
20
2020
2020年7月20日、DAC Biotech社により開発中のADC医薬品候補TROP2-ADC—DAC-002が、NMPAによる臨床試験実施の承認を受けた。適応症は固形悪性腫瘍である。 Medicilonは、TROP2-ADC—DAC-002開発の前臨床薬物動態試験及び毒性試験を実施し、開発プロセスを加速した。
06
29
2020
Chuansha, Shanghai, June 29, 2020. -- Convalife and Medicilon signed a strategic pact, initiating a long-term cooperation between the two companies.
06
16
2020
Date:June 20, 2020 9:00 to 17:00 EST
Location:Virtual Online
06
10
2020
Lamivudine (Brand name: Heganding) comes in 100-mg tablets. It’s a treatment for chronic Heptitis B adult patients with ALT rising, active virus replicating and liver decompensation.